409A Valuation Methods for Pre-Revenue Startups [2026]

Short answer: Pre-revenue startups with a priced round use the backsolve (OPM) method; those without one use the cost (asset-accumulation) approach — the Berkus, Scorecard, and VC methods do not satisfy the 409A safe harbor on their own.

Valuing a company that has never sold a product is one of the hardest problems in 409A practice. The standard tools of corporate valuation — discounting future cash flows, applying revenue multiples, comparing earnings — all assume the company produces something measurable. A pre-revenue startup, by definition, does not. Yet the moment that startup wants to grant a single stock option, IRC Section 409A requires it to establish the fair market value of its common stock using a reasonable method applied consistently. The 409A valuation methods for pre-revenue startups are therefore a distinct toolkit, built specifically for companies whose value lives almost entirely in the future.

This article walks through each of the recognized pre-revenue 409A valuation methods, explains when an appraiser reaches for each one, and clears up the persistent confusion between a real 409A valuation and the back-of-envelope frameworks that founders pick up from investors.

Why Do Pre-Revenue Startups Need a Different Valuation Approach?

Pre-revenue startups require a different 409A approach because traditional income-based methods don't apply: there are no earnings to capitalize and no reliable cash flows to discount. The IRS would not accept a speculative forecast as the sole basis for fair market value.

What a pre-revenue company does have is a capital structure and, often, a recent price that sophisticated investors paid. Those two facts — cap table and most recent transaction — become the foundation of every defensible pre-revenue 409A. The appraiser's job is to translate the preferred stock price into a common stock fair market value, accounting for the rights that separate the two classes and the illiquidity that burdens private shares.

This is why pre-revenue valuations lean heavily on allocation models rather than forecasting models. For a fuller picture of how all three valuation approaches fit together across stages, see our guide to income, market, and cost approaches in 409A.

What valuation methods are used for pre-revenue startups?

For pre-revenue startups, 409A appraisers use three core methods: the backsolve (an OPM-based method that infers value from the most recent priced round), the cost or asset-accumulation approach (which values capital invested to date), and the market approach (which references comparable private transactions). The backsolve dominates when a recent priced round exists; the cost approach fills the gap when one does not.

Each of these 409A valuation methods for pre-revenue startups maps to a different fact pattern. The table below summarizes when each applies, and the sections that follow explain the mechanics.

What Is the Backsolve Method (OPM Backsolve) for Pre-Revenue Startups?

The backsolve is the standard 409A method for pre-revenue startups that have closed a priced equity round. It takes the price investors paid for preferred stock as the most reliable evidence of value, then uses an Option Pricing Model to solve backward for the total equity value that makes that preferred price consistent with the waterfall.

Once total equity value is pinned down, the same OPM allocates value to common stock, which sits behind preferred in the liquidation waterfall. Common stock lacks the liquidation preferences, dividend rights, and protective provisions of preferred — so the backsolve always assigns a materially lower per-share value to common than the preferred price. The IRS and auditors find this approach persuasive because the value is grounded in what informed parties actually paid. This ties into the broader 409A valuation methodology framework used across all stages.

What Is the Cost (Asset-Accumulation) Approach for Pre-Revenue 409A?

The cost (asset-accumulation) approach is the primary 409A method for bootstrapped and SAFE-only companies that have no priced round. It values the company by totaling the capital invested and assets accumulated: cash, equipment, capitalized development costs, and identifiable intangibles like filed patents.

The premise is that, absent external validation of value, a buyer would pay roughly what it would cost to recreate the asset base. For an idea-stage company with little more than incorporation documents and a prototype, this typically produces a very low common-stock FMV — often $0.01–$0.05 per share.

The cost approach has a clear ceiling: it captures what has been spent, not what the company might become. As soon as a startup raises a priced round, the backsolve supersedes the cost approach, because the market has now spoken. For more on how the earliest-stage companies are valued, see our guide to 409A valuation for seed and pre-seed startups.

How Does the Market Approach Work for Pre-Revenue Startups?

The market approach values a startup by reference to what similar companies have been worth in recent transactions. For a pre-revenue company, the appraiser cannot use revenue multiples — there is no revenue — so the market approach instead relies on comparable private financings: recent seed or Series A rounds for companies at a similar stage, in a similar sector, with a similar risk profile.

In practice, the market approach usually plays a supporting role for pre-revenue companies rather than serving as the primary method. Genuinely comparable pre-revenue transactions are hard to find, the terms are rarely fully disclosed, and the dispersion in early-stage valuations is enormous. An appraiser will more often use comparable-transaction data to corroborate a backsolve result — confirming that the implied valuation is reasonable relative to the market — than to drive the conclusion outright. Where biotech and deep-tech companies are concerned, comparable financings can carry more weight because the milestones (a completed Phase I trial, a granted patent) are more standardized. Our 409A valuation for biotech startups guide covers those sector-specific adjustments.

What Are Berkus, Scorecard, and the VC Method — and Can They Replace a 409A?

Berkus, Scorecard, and the VC method cannot replace a 409A valuation. Each estimates a pre-money enterprise value, but none performs the three steps that make a 409A defensible: allocating value to common stock across the cap-table waterfall, applying a DLOM, and documenting methodology per the AICPA Practice Aid.

These frameworks were designed for angel investor negotiations. The Berkus method assigns dollar values to five qualitative risk factors. The Scorecard method adjusts a regional average pre-money valuation based on peer comparisons. The VC method works backward from a hypothetical exit and target return multiple. A 409A appraiser may use any of these as a sanity check, but a self-prepared valuation built solely on these heuristics does not satisfy the independent appraisal safe harbor.

How do you value a pre-revenue startup with no funding?

For a pre-revenue startup with no priced round, appraisers use the cost (asset-accumulation) approach, valuing the cash, equipment, and intangible assets invested to build the company so far. The resulting enterprise value is typically modest, which produces a very low common-stock fair market value — often $0.01 to $0.05 per share for an idea-stage company.

That low value is a feature, not a bug, for a founder issuing early options: it sets a low strike price that maximizes the upside for the first employees while still being fully defensible under 409A, because it rests on a documented method applied by a qualified appraiser. As the company raises capital and accumulates evidence of value — a priced round, signed customer contracts, granted intellectual property — subsequent valuations will climb, and the method will shift from cost to backsolve.

What Are Typical Pre-Revenue 409A Valuation Ranges by Stage?

While every company is different, pre-revenue 409A common-stock values cluster in recognizable ranges. Understanding these helps founders sanity-check whether a draft report reflects reasonable assumptions. For a deeper dataset, see our 409A valuation benchmarks for seed-stage startups.

These ranges assume a typical software or technology cap table. Capital-intensive companies, those with unusual preference stacks, or those with large outstanding SAFE balances can fall outside them, which is exactly why a qualified appraiser — rather than a rule of thumb — is required.

What Are the Most Common Mistakes in Pre-Revenue 409A Valuations?

Equating the preferred price with common stock value. The most frequent founder error is assuming that because investors paid, say, $1.00 per preferred share, the common stock must also be worth roughly $1.00. The entire point of the backsolve and OPM allocation is to separate these. Common stock is worth substantially less because it sits behind preferred in the liquidation waterfall and lacks preferred's protective rights.

Ignoring outstanding SAFEs and convertible notes. Pre-revenue cap tables are often littered with SAFEs and notes that have not yet converted. These dilute common stock and must be modeled with their actual conversion terms. Omitting them inflates the common-stock value and can make the report indefensible.

Using a stale valuation after a material event. A priced round is a textbook material event. Granting options off a pre-round valuation after closing a new round — or more than 12 months after the last appraisal — forfeits safe harbor reliance.

Treating a self-prepared spreadsheet as a 409A. A Berkus or Scorecard figure, however thoughtfully derived, does not constitute an independent appraisal. Under Treasury Regulations Section 1.409A-1(b)(5)(iv), only a valuation by a qualified independent appraiser carries the rebuttable presumption of reasonableness that protects employees from 409A penalties.